Identify critical genes of breast cancer and corresponding leading natural product compounds of potential therapeutic targets
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-11035-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Xiaokai Fan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery/Otolaryngology, Longgang Central Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Biological Products, Antineoplastic Agents. Die Arbeit nennt 24 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science, Technology and Innovation Commission of Shenzhen Municipality, Shenzhen Medical Research Funds.
Abstract (Originalsprache)
Breast cancer is a leading cause of cancer mortality among women globally, with over 2.26 million new cases annually, according to GLOBOCAN 2020. This accounts for approximately 25% of all new female cancers and 15.5% of female cancer deaths. To address this critical public health challenge, we conducted a multi-omics study aimed at identifying hub genes, therapeutic targets, and potential natural product-based therapies. We employed weighted gene co-expression network analysis (WGCNA) and differential gene expression analysis to pinpoint hub genes in breast cancer. Regulatory networks for these genes were constructed by re-analyzing chromatin immunoprecipitation sequencing (ChIP-seq) data from breast cancer cell lines. Additionally, single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) were utilized to characterize hub gene expression profiles and their relationships with immune cell clusters and tumor microenvironments. Survival analysis based on mRNA and protein expression levels identified prognostic factors and potential therapeutic targets. Lastly, large-scale virtual screening of natural product compounds revealed leading compounds that target squalene epoxidase (SQLE). Our multi-omics analysis paves the way for more effective clinical treatments for breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery/Otolaryngology, Longgang Central Hospital, Shenzhen, China.
- Shenzhen Laboratory of Tumor Cell Biology, Institutes of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
- Center for Intelligent Medicine Research, Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life Sciences, Fudan University, Shanghai, China.
- Cancer Centre, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau SAR, China.
- Department of General Surgery/Otolaryngology, Longgang Central Hospital, Shenzhen, China. guiyang1981@hotmail.com.
- Shenzhen Laboratory of Tumor Cell Biology, Institutes of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. liang.chen@siat.ac.cn.
Förderung
- National Key Research and Development Program of China
- Science, Technology and Innovation Commission of Shenzhen Municipality
- Shenzhen Medical Research Funds
Zitieren
APA
Fan, X., Xin, L., Yu, X., Liu, M., Shim, J. S., Yang, G., & Chen, L. (2025). Identify critical genes of breast cancer and corresponding leading natural product compounds of potential therapeutic targets. Molecular Diversity. https://doi.org/10.1007/s11030-024-11035-z
Vancouver
Fan X, Xin L, Yu X, Liu M, Shim JS, Yang G, et al. Identify critical genes of breast cancer and corresponding leading natural product compounds of potential therapeutic targets. Molecular Diversity. 2025. doi:10.1007/s11030-024-11035-z
BibTeX
@article{Fan2025,
author = {Fan, Xiaokai and Xin, Le and Yu, Xuan and Liu, Maoxuan and Shim, Joong Sup and Yang, Gui and Chen, Liang},
title = {Identify critical genes of breast cancer and corresponding leading natural product compounds of potential therapeutic targets},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-11035-z}
}
EUVIMED